Patella

ReLive Biotechnologies Announces NDA Approval of SpheChon 10-70 spheroids/cm² by the HSA in Singapore, Marking a Milestone in ReLive’s Global Endeavors

Retrieved on: 
Tuesday, January 23, 2024

This approval is a testament to ReLive's commitment to advancing regenerative cell therapies and marks a significant step in expanding our global reach.

Key Points: 
  • This approval is a testament to ReLive's commitment to advancing regenerative cell therapies and marks a significant step in expanding our global reach.
  • SpheChon represents a major advancement in cell therapy for cartilage repair, offering new hope and enhanced treatment options by using the patients’ own cells to regain an active life.
  • This approval by HSA reflects ReLive’s dedication to upholding the highest standards of safety, efficacy, and quality in our innovative treatment solutions.
  • Quote from ReLive’s CEO, Dr. Xing Zhao: “The approval in Singapore is more than just a regulatory milestone.

26 Tissue Donors Who Gave the Gift of Life and Two Tissue Recipients Whose Lives Were Transformed by the Power of Donation will Participate in the 2024 OneLegacy Donate Life Float on New Year’s Day

Retrieved on: 
Friday, December 22, 2023

The two tissue recipients, along with 26 floral portraits or floragraphs of cornea and tissue donors, represent the healing and transformational power of tissue donation.

Key Points: 
  • The two tissue recipients, along with 26 floral portraits or floragraphs of cornea and tissue donors, represent the healing and transformational power of tissue donation.
  • “We are honored to co-sponsor tissue recipient Joceline Pérez Hernández on the 2024 OneLegacy Donate Life float.
  • The 2024 OneLegacy Donate Life Float tissue recipients include the following float riders:
    Joceline Perez Hernandez is a bone tissue recipient from San Bernardino.
  • The 2024 float will honor 56 participants, including 22 riders and walkers who are either living donors, or organ and tissue recipients.

Completion of First in Human Clinical Trial Two-Year Follow-up for the LIFT Implant

Retrieved on: 
Tuesday, November 7, 2023

KENTFIELD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc. a clinical stage medical device company, today announced successful completion of two-year follow up on subjects enrolled in the first-in-human clinical trial.

Key Points: 
  • KENTFIELD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- ZKR Orthopedics, Inc. a clinical stage medical device company, today announced successful completion of two-year follow up on subjects enrolled in the first-in-human clinical trial.
  • The 18-patient trial conducted in the European Union was designed to evaluate the safety of the LIFT implant technology on patients with varying stages of patellofemoral cartilage degeneration.
  • Further, the trial collected data related to pain, function, and radiographic imaging to evaluate the performance of the LIFT implant as a surgical alternative.
  • The trial will evaluate the performance of the LIFT implant technology compared to tibial tubercle osteotomy in patients aged 25-65 with cartilage degeneration and osteoarthritis of the patellofemoral compartment of the knee.

A Leap Forward in Pet Care: Lick Sleeve's E-Collar Alternative Now Available Through Movora

Retrieved on: 
Wednesday, November 1, 2023

AUSTIN, Texas, Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking development for post-surgery pet care, Lick Sleeve has named Movora as its exclusive veterinary distribution partner for North America.

Key Points: 
  • AUSTIN, Texas, Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking development for post-surgery pet care, Lick Sleeve has named Movora as its exclusive veterinary distribution partner for North America.
  • This partnership makes Lick Sleeve's innovative post-surgery protective leg sleeves for dogs widely available to veterinarians across the continent, offering a humane and efficient alternative to the traditional "cone of shame."
  • One of the key advantages of Lick Sleeve is its ability to improve pet owner compliance.
  • This groundbreaking partnership between Lick Sleeve and Movora promises to revolutionize post-surgery pet care, making it more comfortable and less stressful for our beloved four-legged friends.

Lick Sleeve Names Movora Exclusive Veterinary Distributor for North America

Retrieved on: 
Monday, October 16, 2023

ST. AUGUSTINE, Fla., Oct. 16, 2023 /PRNewswire/ -- Movora is honored to partner with Lick Sleeve and Dr. David Allman, DVM, DACVS-SA, as their exclusive veterinary distribution partner for North America. Lick Sleeve® patented leg sleeves for dogs protect the patient's surgical site to offer a better approach to recovery than the dreaded "cone of shame."

Key Points: 
  • ST. AUGUSTINE, Fla., Oct. 16, 2023 /PRNewswire/ -- Movora is honored to partner with Lick Sleeve and Dr. David Allman, DVM, DACVS-SA, as their exclusive veterinary distribution partner for North America.
  • Lick Sleeve® patented leg sleeves for dogs protect the patient's surgical site to offer a better approach to recovery than the dreaded "cone of shame."
  • The addition of Lick Sleeve protective recovery sleeves to the Movora line lets animal hospitals incorporate them into their recovery protocols.
  • As Dr. Allman notes, "Pet owners are three times more likely to use the Lick Sleeve than traditional e-collars.

ALLOSOURCE ANNOUNCES POSTER FEATURING PROCHONDRIX CR OSTEOCHONDRAL ALLOGRAFT CLINICAL OUTCOMES AT THE 17TH INTERNATIONAL CARTILAGE REGENERATION & JOINT PRESERVATION SOCIETY (ICRS) WORLD CONGRESS

Retrieved on: 
Friday, September 8, 2023

ProChondrix CR Cryopreserved Osteochondral Allograft is a single-stage, cryopreserved, articular cartilage allograft.

Key Points: 
  • ProChondrix CR Cryopreserved Osteochondral Allograft is a single-stage, cryopreserved, articular cartilage allograft.
  • The poster titled, "ProChondrix® CR Prospective Clinical Outcomes for the Repair of Focal Articular Cartilage Defects in the Knee" evaluates the prospective clinical outcomes of patients who received ProChondrix CR in focal cartilage lesions of the patella and femoral condyle of the knee.
  • "This ICRS poster showcases the promising results surgeons are having treating their patients with ProChondrix CR," said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Affairs.
  • For additional detail on ProChondrix CR's clinical outcomes visit the ICRS poster showcase or E-Poster online #208.

Knee pain: here’s why it happens, and how you can fix it

Retrieved on: 
Wednesday, September 6, 2023

Global estimates suggest more than one in five people over the age of 40 have a form of chronic knee pain.

Key Points: 
  • Global estimates suggest more than one in five people over the age of 40 have a form of chronic knee pain.
  • But just because knee pain is common doesn’t mean you have to live with it.
  • No matter the cause, tackling knee pain is often relatively straightforward when you know what to do.
  • People with inflammatory arthritis such as gout or rheumatoid arthritis can have flare-ups that cause knee pain.

Managing pain

    • The best way of managing knee pain depends on the cause.
    • Keep strong and active: Strengthening the muscles around your knee will noticeably reduce pain and stiffness.
    • Modify your activities: Some people find pacing their activities (such as doing certain tasks when your knee pain isn’t as bad, or spacing out activities that you know may cause pain), using walking aids or wearing shoes with shock-absorbing soles (such as good trainers) to be useful.
    • But these changes may only make a small difference in managing knee pain.
    • If you find your knee pain is made worse by your work, you may also want to make some changes to the way you normally do things to help reduce pain.

Preventing pain

    • But if your knee pain is due to a problem such as a ruptured ligament or advanced osteoarthritis, knee surgery may be recommended.
    • For people with advanced osteoarthritis, operations such as total knee replacement can lead to big improvements in pain, ability to carry out daily activities and overall wellbeing.
    • GPs may recommend painkillers in some circumstances – for example if your knee pain is stopping you exercising.

Prime Therapeutics hires Matt Patella to lead employer account sales and account management

Retrieved on: 
Monday, March 6, 2023

Patella brings more than 20 years of sales leadership including account management and new business development to his role.

Key Points: 
  • Patella brings more than 20 years of sales leadership including account management and new business development to his role.
  • Patella will be responsible for the employer group market sales strategy including growth and retention.
  • Patella brings previous health care, consultant and PBM leadership experience to his new role at Prime.
  • "Matt's experience is sure to lead to positive client experiences and productive working partnerships for those we serve."

Innovative Soft Tissue Healing Treatments Now Available for Chronic Pain Sufferers in Virginia and Mid-Atlantic Region

Retrieved on: 
Wednesday, December 14, 2022

SAM provides mechanical stimulation of tissue to facilitate the remodeling process every day for a more rapid and robust healing response.

Key Points: 
  • SAM provides mechanical stimulation of tissue to facilitate the remodeling process every day for a more rapid and robust healing response.
  • The ZetrOZ sam®x1 device increases blood vessel diameters to bring more oxygenated blood to the healing site, removing cytokine enzymes and cellular waste, and expediting the healing process.
  • "We're incredibly happy to see SAM technology and the sam®x1 device providing healing and relief in yet another setting," Lewis said.
  • ZetrOZ Systems is leading healing innovations in sports medicine and developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®).

Outlook on the Advanced Therapy Medicinal Products Global Market to 2027 - Featuring F. Hoffmann-La Roche, Bluebird Bio, UniQure and Kolon TissueGene Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022

Furthermore, market players continue to undertake various market strategies to boost the adoption of their products.

Key Points: 
  • Furthermore, market players continue to undertake various market strategies to boost the adoption of their products.
  • For instance, in January 2021, Vericel Corporation announced the expansion of the medical coverage policy for MACI by United Healthcare.
  • The expansion includes coverage for patients with multiple cartilage defects in the knee and symptomatic full-thickness cartilage defects in the patella.
  • These developments are anticipated to boost the United States market to a great extent in the future market.